Business context and reporting period
China Pharma Holdings, Inc. manufactures and markets generic and branded pharmaceuticals and biochemical products, primarily in China through its subsidiary Helpson. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2015; balance-sheet comparisons are with December 31, 2014. Amounts below are U.S. dollars.
Key financial metrics
| Metric | Three months ended Sept. 30, 2015 | Nine months ended Sept. 30, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | $4.48 million | $15.85 million | $5.57 million and $18.80 million |
| Gross profit / margin | $0.32 million / 7.2% | $1.33 million / 8.4% | $1.51 million / 27.1%; $6.59 million / 35.0% |
| Operating loss | $3.89 million | $15.36 million | $5.99 million and $16.86 million |
| Net loss | $4.15 million | $16.24 million | $6.33 million and $17.36 million |
| Loss per share, basic and diluted | $0.10 | $0.37 | $0.15 and $0.40 |
| Operating cash flow | Not presented for quarter | $0.65 million | $2.60 million |
- Quarterly revenue fell 20% and nine-month revenue fell 16% year over year. Nine-month cost of revenue rose to 80% of revenue from 65%, and gross profit declined about 80%.
- Inventory obsolescence charges were $0.44 million for the quarter and $1.86 million for the nine months; none was recorded in the comparable 2014 periods. Management estimated nine-month gross margin would have been about 20% excluding the obsolescence charge.
- Bad-debt expense was $3.92 million for the quarter and $13.13 million for the nine months. The allowance for doubtful accounts reached $44.92 million, compared with $33.35 million at year-end 2014.
- Cash and cash equivalents were $5.74 million, versus $5.30 million at year-end. Nine-month cash provided by operations was $0.65 million; investing activities used approximately $0.003 million, and cash increased $0.42 million after exchange-rate effects.
- Current assets were $39.86 million and current liabilities $16.13 million. Total liabilities were $25.87 million. Debt included $4.72 million of short-term notes and $12.59 million under the construction loan facility, of which $3.15 million was current.
- Net accounts receivable was $11.78 million, down from $24.85 million at year-end, and inventory was $12.29 million, down from $15.32 million. The receivables balance is presented net of a substantial allowance.
Material changes versus prior periods
- Management attributed lower sales to missed drug tenders during GMP upgrades, uncertainty around healthcare reform and cost controls, and market fluctuations affecting products including Cefaclor, Ozagrel, Candesartan, and Tiopronin.
- GMP compliance raised production costs, including energy and depreciation, while quarterly and nine-month inventory obsolescence charges further reduced margins.
- Operating and net losses narrowed year over year for both reported periods. For the quarter, a $1.66 million government subsidy was a major offset to weaker revenue and margins. For the nine months, lower R&D expense and the absence of the prior-year natural-disaster loss helped offset lower revenue and higher obsolescence.
- Nine-month selling expense increased 44% to $3.16 million; R&D expense declined to $0.74 million from $2.53 million. Foreign-currency translation reduced comprehensive results by $3.20 million for the nine months.
Outlook, risks and contingencies
- Management believed operating cash flow would meet operating needs and anticipated capital expenditures for the next 12 months, but stated that a shortfall against its plan could require additional capital or spending reductions. Additional financing was not assured on acceptable terms.
- The company said CFDA approval timelines for pipeline products had lengthened, with additional materials and trials required. Typical approval can take two to five years from contract signing; no new formula production approvals were obtained in the first nine months of 2015. GMP certificates for upgraded granule and cephalosporin lines were expected by year-end 2015; the old-factory dry-powder injectable line was expected to be upgraded the following year.
- Management cited slowing pharmaceutical-industry growth, drug-price and healthcare cost-control pressure, tender uncertainty, and changing PRC policies. All revenue is denominated in RMB; currency conversion and remittance abroad are subject to government controls. The RMB declined 4.4% against the U.S. dollar in August 2015.
- Receivables remain a key risk: $11.4 million was more than 90 days past due, and 77.8% of receivables in the disclosed aging table was over 720 days old. Two customers represented 17.6% and 10.8% of receivables at quarter-end. Management stated that overdue payments from government-backed hospitals are generally expected to be collected, but collection timing is uncertain.
- The company had approximately $4.2 million in commitments payable over the next four years as milestones are completed under medical-formula contracts. It reported no off-balance-sheet arrangements.
- After quarter-end, the RMB 30 million revolving credit line was renewed, with two equal installments due in September and October 2016 and an annual interest rate of 5.06%; the CEO and board chair personally guaranteed it. The filing also notes that the company’s cash is considered indefinitely reinvested in Helpson and is not expected to be available to the parent for dividends or other payments.
Important facts for investors to verify
- Collection progress on aged receivables, adequacy of the $44.92 million bad-debt allowance, and the basis for management’s expectation of eventual collection.
- Whether sales recover after GMP upgrades and whether tender participation, pricing pressure, and healthcare reforms continue to constrain revenue.
- Actual production costs and inventory quality, including further obsolescence charges and the sustainability of reported margins.
- Milestone progress and refund protections for the $41.34 million in advances for intangible assets, as well as the timing and likelihood of CFDA approvals.
- Ability to service construction-loan principal installments and maintain liquidity, given restricted access to PRC subsidiary cash and the company’s reliance on operating cash generation.
- Customer and supplier concentration, currency-control exposure, and the impact of RMB movements on reported results and cash available to the parent.